Pesquisas alternativas:
level rather » levels rather (Expandir a Pesquisa), level rate (Expandir a Pesquisa), level catheter (Expandir a Pesquisa)
novel ether » novel tethered (Expandir a Pesquisa), novelli ethel (Expandir a Pesquisa), novel fathers (Expandir a Pesquisa)
does novel » does nose (Expandir a Pesquisa)
drug does » drug doses (Expandir a Pesquisa), drugs does (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
live ther » live them (Expandir a Pesquisa), live rather (Expandir a Pesquisa), liver other (Expandir a Pesquisa)
level rather » levels rather (Expandir a Pesquisa), level rate (Expandir a Pesquisa), level catheter (Expandir a Pesquisa)
novel ether » novel tethered (Expandir a Pesquisa), novelli ethel (Expandir a Pesquisa), novel fathers (Expandir a Pesquisa)
does novel » does nose (Expandir a Pesquisa)
drug does » drug doses (Expandir a Pesquisa), drugs does (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
live ther » live them (Expandir a Pesquisa), live rather (Expandir a Pesquisa), liver other (Expandir a Pesquisa)
1
Por Rather, Irfan A., Bajpai, Vivek K., Huh, Yun Suk, Han, Young-Kyu, Bhat, Eijaz A., Lim, Jeongheui, Paek, Woon K., Park, Yong-Ha
Publicado no Front Microbiol (2018)
“... by the treatment of a standard drug clobetasol and SEL001. Further, mRNA expression analysis indicated a...”Publicado no Front Microbiol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
2
“... on gd12 than gd8. Each microvascular level responded to each agonist on gd8 and gd12. At gd12...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Pertwee, Roger G.
Publicado em 2005
“...(1) and/or CB(2) receptor agonist or antagonist that does or does not readily cross the blood brain...”Publicado em 2005
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
4
Por Charrier, Cédric, Salisbury, Anne-Marie, Savage, Victoria J., Duffy, Thomas, Moyo, Emmanuel, Chaffer-Malam, Nathan, Ooi, Nicola, Newman, Rebecca, Cheung, Jonathan, Metzger, Richard, McGarry, David, Pichowicz, Mark, Sigerson, Ralph, Cooper, Ian R., Nelson, Gary, Butler, Hayley S., Craighead, Mark, Ratcliffe, Andrew J., Best, Stuart A., Stokes, Neil R.
Publicado no Antimicrob Agents Chemother (2017)
“...The novel bacterial topoisomerase inhibitor class is an investigational type of antibacterial...”Publicado no Antimicrob Agents Chemother (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
“... circumstances of PWID rather than rigid exclusion criteria will determine the level of success of any model...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
6
Por Supp, Gernot G., Higgen, Focko L., Hipp, Joerg F., Engel, Andreas K., Siegel, Markus
Publicado no Front Pharmacol (2018)
“... AEPs during remifentanil medication. This decrease was predicted by drug dose, rather than sedation...”Publicado no Front Pharmacol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por César-Razquin, Adrián, Girardi, Enrico, Yang, Mi, Brehme, Marc, Saez-Rodriguez, Julio, Superti-Furga, Giulio
Publicado no Front Pharmacol (2018)
“...The interplay between drugs and cell metabolism is a key factor in determining both compound...”Publicado no Front Pharmacol (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Seeger, J M, Brinkmann, K, Yazdanpanah, B, Haubert, D, Pongratz, C, Coutelle, O, Krönke, M, Kashkar, H
Publicado em 2010
“... in different tumour entities. However, rather than being an adverse prognostic marker, recent data suggest...”Publicado em 2010
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Publicado no Drug Des Devel Ther (2016)
“... for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
“..., BMI, drug dose and time from drug intake were recorded. RESULTS: All patients had a measurable...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
“... a novel mechanism for the control of disulfide-based drug release rates. Therapy experiments...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
Por Csete, Joanne, Kamarulzaman, Adeeba, Kazatchkine, Michel, Altice, Frederick, Balicki, Marek, Buxton, Julia, Cepeda, Javier, Comfort, Megan, Goosby, Eric, Goulão, João, Hart, Carl, Horton, Richard, Kerr, Thomas, Lajous, Alejandro Madrazo, Lewis, Stephen, Martin, Natasha, Mejía, Daniel, Mathiesson, David, Obot, Isidore, Ogunrombi, Adeolu, Sherman, Susan, Stone, Jack, Vallath, Nandini, Vickerman, Peter, Zábranský, Tomáš, Beyrer, Chris
Publicado no Lancet (2016)
“... drug laws, does not distinguish between drug use and drug abuse. A 2015 report by the UN High...”Publicado no Lancet (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por Lou, Bin, Liu, Qi, Hou, Jiahui, Kabir, Inamul, Liu, Peipei, Ding, Tingbo, Dong, Jibin, Mo, Mingguang, Ye, Deyong, Chen, Yang, Bui, Hai H., Roth, Kenneth, Cao, Yu, Jiang, Xian-Cheng
Publicado no J Biol Chem (2018)
“...2-Hydroxy-oleic acid (2OHOA) is a potent anticancer drug that induces cancer cell cycle arrest...”Publicado no J Biol Chem (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
14
“... way of gaining bargaining power in drug purchasing, rather than promoting the increase in scale...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
“...BACKGROUND: We determined whether the market exclusivity incentive of the European Orphan Drug...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Grönholm, Juha, Pagni, Philippe P., Pham, Minh N., Gibson, Claire B., Macomber, Paul F., Vela, José Luis, von Herrath, Matthias, Lenardo, Michael J.
Publicado no Diabetologia (2017)
“.... administration of MII accelerates rather than prevents diabetes. High-dose i.v. treatment did not prevent disease...”Publicado no Diabetologia (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Sankaranarayanan, Rajiv, Kirkwood, Graeme, Visweswariah, Rajaverma, Fox, David J.
Publicado no Curr Cardiol Rev (2015)
“... risk from AF is due to the “bad company it keeps” i.e. the associated co-morbidities rather than AF...”Publicado no Curr Cardiol Rev (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Kosilov, Kirill Vladimirovich, Loparev, Sergey, Kuzina, Irina, Shakirova, Olga, Zhuravskaya, Nataliya, Lobodenko, Alexandra
Publicado no Ther Adv Urol (2016)
“... in antimuscarinic (AM) drug treatment. BACKGROUND: The prevalence of urge urinary incontinence (UUI) is an average...”Publicado no Ther Adv Urol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
“... themselves involved at various levels in institutional drug-screening programs. Several legal, moral...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Dinoso, J. B., Kim, S. Y., Wiegand, A. M., Palmer, S. E., Gange, S. J., Cranmer, L., O'Shea, A., Callender, M., Spivak, A., Brennan, T., Kearney, M. F., Proschan, M. A., Mican, J. M., Rehm, C. A., Coffin, J. M., Mellors, J. W., Siliciano, R. F., Maldarelli, F.
Publicado em 2009
“... that levels of viremia were not reduced by ART intensification with any of 3 different antiretroviral drugs...”Publicado em 2009
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo